Free Trial

Erin Wilson Analyst Performance

Analyst at Morgan Stanley

Erin Wilson is a stock analyst at Morgan Stanley focused in the medical sector, covering 10 publicly traded companies. Over the past year, Erin Wilson has issued 4 stock ratings, including and hold recommendations. While full access to Erin Wilson's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Erin Wilson's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
21 Last 9 Years
Buy Recommendations
61.90% 13 Buy Ratings
Companies Covered
10 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy4.8%1 ratings
Buy57.1%12 ratings
Hold28.6%6 ratings
Sell9.5%2 ratings

Out of 21 total stock ratings issued by Erin Wilson at Morgan Stanley, the majority (57.1%) have been Buy recommendations, followed by 28.6% Hold, 9.5% Sell, and 4.8% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
80.0% of companies on NASDAQ
8 companies
NYSE
20.0% of companies on NYSE
2 companies

Erin Wilson, an analyst at Morgan Stanley, currently covers 10 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
70.0%
Miscellaneous
2 companies
20.0%
Computer and Technology
1 company
10.0%

Erin Wilson of Morgan Stanley specializes in stock coverage within the Medical sector, with additional focus on and Computer and Technology companies.

Coverage Industries

IndustryPercentage
Miscellaneous
2 companies
20.0%
INTERNET SOFTWARE
1 company
10.0%
MED/DENTAL - SUPP
1 company
10.0%
COMMERCIAL PHYSICAL RESEARCH
1 company
10.0%
MEDICAL SERVICES
1 company
10.0%
MED - DRUGS
1 company
10.0%
MED PRODUCTS
1 company
10.0%
MEASURING & CONTROLLING DEVICES
1 company
10.0%
PHARMACEUTICAL PREPARATIONS
1 company
10.0%

Erin Wilson's Ratings History at Morgan Stanley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Rapid7, Inc. stock logo
RPD
Rapid7
9/2/2025Lower Price Target$20.57$22.00Equal Weight
Rapid7, Inc. stock logo
RPD
Rapid7
5/13/2025Boost Price Target$24.69$28.00Equal Weight
Rapid7, Inc. stock logo
RPD
Rapid7
4/16/2025Lower Price Target$22.53$26.00Equal Weight
Rapid7, Inc. stock logo
RPD
Rapid7
3/18/2025Initiated Coverage$28.39$33.00Equal Weight